Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Warren Olanow
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Procedures
Living Beings
Sign-in to see full Profile
Network (preview)
20
Hauser, Robert
18
Goetz, Christopher
17
Koller, William
17
Kordower, Jeffrey
17
McNaught, Kevin St
16
Obeso, Jose
15
Perl, Daniel
11
Mytilineou, Catherine
11
Lang, Anthony
11
Jenner, Peter
11
Schapira, Anthony
10
Brin, Mitchell
9
Fahn, Stanley
9
Stocchi, Fabrizio
8
Shashidharan, Pullanipally
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Warren Olanow (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Olanow C Warren; Kordower Jeffrey H
Modeling Parkinson's disease.
Annals of neurology 2009;66(4):432-6.
-
2009: Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Experimental neurology 2009;219(2):533-42.
-
2009: Olanow C Warren; Rascol Olivier; Hauser Robert; Feigin Paul D; Jankovic Joseph; Lang Anthony; Langston William; Melamed Eldad; Poewe Werner; Stocchi Fabrizio; Tolosa Eduardo;
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
The New England journal of medicine 2009;361(13):1268-78.
-
2009: Chu Yaping; Dodiya Hemraj; Aebischer Patrick; Olanow C Warren; Kordower Jeffrey H
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Neurobiology of disease 2009;35(3):385-98.
-
2009: Olanow C Warren; Prusiner Stanley B
Is Parkinson's disease a prion disorder?
Proceedings of the National Academy of Sciences of the United States of America 2009;106(31):12571-2.
-
2009: Olanow C Warren; Stern Matthew B; Sethi Kapil
The scientific and clinical basis for the treatment of Parkinson disease (2009).
Neurology 2009;72(21 Suppl 4):S1-136.
-
2009: McNaught K S; Olanow C W
Withdrawal of figure 2 from McNaught and Olanow's article, "Proteasome inhibitor-induced model of Parkinson's disease" (Ann Neurol 2006;60:243-247).
Annals of neurology 2009;65(4):485.
-
2009: Hälbig T D; Tse W; Frisina P G; Baker B R; Hollander E; Shapiro H; Tagliati M; Koller W C; Olanow C W
Subthalamic deep brain stimulation and impulse control in Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(4):493-7.
-
2009: Olanow C Warren
Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Neurology 2009;72(7 Suppl):S59-64.
-
2009: Olanow C Warren; Gracies Jean-Michel; Goetz Christopher G; Stoessl A Jon; Freeman Thomas; Kordower Jeffrey H; Godbold James; Obeso Jose A
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
Movement disorders : official journal of the Movement Disorder Society 2009;24(3):336-43.
-
2008: Obeso Jose A; Marin Concepcio; Rodriguez-Oroz C; Blesa Javier; Benitez-Temiño B; Mena-Segovia Juan; Rodríguez Manuel; Olanow C Warren
The basal ganglia in Parkinson's disease: current concepts and unexplained observations.
Annals of neurology 2008;64 Suppl 2():S30-46.
-
2008: Olanow C Warren; Kieburtz Karl; Schapira Anthony H V
Why have we failed to achieve neuroprotection in Parkinson's disease?
Annals of neurology 2008;64 Suppl 2():S101-10.
-
2008: Schapira Anthony H V; Olanow C Warren
Drug selection and timing of initiation of treatment in early Parkinson's disease.
Annals of neurology 2008;64 Suppl 2():S47-55.
-
2008: Olanow C Warren; Stern Matthew B
Parkinson's disease: unresolved issues.
Annals of neurology 2008;64 Suppl 2():S1-2.
-
2008: Kordower Jeffrey H; Chu Yaping; Hauser Robert A; Olanow C Warren; Freeman Thomas B
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report.
Movement disorders : official journal of the Movement Disorder Society 2008;23(16):2303-6.
-
2008: Goetz Christopher G; Tilley Barbara C; Shaftman Stephanie R; Stebbins Glenn T; Fahn Stanley; Martinez-Martin Pablo; Poewe Werner; Sampaio Cristina; Stern Matthew B; Dodel Richard; Dubois Bruno; Holloway Robert; Jankovic Joseph; Kulisevsky Jaime; Lang Anthony E; Lees Andrew; Leurgans Sue; LeWitt Peter A; Nyenhuis David; Olanow C Warren; Rascol Olivier; Schrag Anette; Teresi Jeanne A; van Hilten Jacobus J; LaPelle Nancy;
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Movement disorders : official journal of the Movement Disorder Society 2008;23(15):2129-70.
-
2008: Olanow C Warren; Hauser Robert A; Jankovic Joseph; Langston William; Lang Anthony; Poewe Werner; Tolosa Eduardo; Stocchi Fabrizio; Melamed Eldad; Eyal Eli; Rascol Olivier
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Movement disorders : official journal of the Movement Disorder Society 2008;23(15):2194-201.
-
2008: Kordower Jeffrey H; Chu Yaping; Hauser Robert A; Freeman Thomas B; Olanow C Warren
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.
Nature medicine 2008;14(5):504-6.
-
2008: Nair Venugopalan D; Olanow C Warren
Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses.
The Journal of biological chemistry 2008;283(22):15469-78.
-
2008: Marks William J; Ostrem Jill L; Verhagen Leonard; Starr Philip A; Larson Paul S; Bakay Roy Ae; Taylor Robin; Cahn-Weiner Deborah A; Stoessl A Jon; Olanow C Warren; Bartus Raymond T
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Lancet neurology 2008;7(5):400-8.
-
2008: Tse Winona; Libow Leslie S; Neufeld Richard; Lesser Gerson; Frank Judith; Dolan Susan; Tarshish Chaim; Gracies Jean-Michel; Olanow C Warren; Koller William C; Hälbig Thomas D
Prevalence of movement disorders in an elderly nursing home population.
Archives of gerontology and geriatrics 2008;46(3):359-66.
-
2008: Kordower Jeffrey H; Olanow C Warren
Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?
Experimental neurology 2008;209(1):34-40.
-
2008: Stocchi Fabrizio; Tagliati Michele; Olanow C Warren
Treatment of levodopa-induced motor complications.
Movement disorders : official journal of the Movement Disorder Society 2008;23 Suppl 3():S599-612.
-
2008: Olanow C Warren; Lees Andrew; Obeso Jose
Levodopa therapy for Parkinson's disease: challenges and future prospects.
Movement disorders : official journal of the Movement Disorder Society 2008;23 Suppl 3():S495-6.
-
2008: Olanow C Warren
Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Movement disorders : official journal of the Movement Disorder Society 2008;23 Suppl 3():S613-22.
-
2007: Dubois Bruno; Burn David; Goetz Christopher; Aarsland Dag; Brown Richard G; Broe Gerald A; Dickson Dennis; Duyckaerts Charles; Cummings Jefferey; Gauthier Serge; Korczyn Amos; Lees Andrew; Levy Richard; Litvan Irene; Mizuno Yoshikuni; McKeith Ian G; Olanow C Warren; Poewe Werner; Sampaio Cristina; Tolosa Eduardo; Emre Murat
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.
Movement disorders : official journal of the Movement Disorder Society 2007;22(16):2314-24.
-
2007: Li Xianting; Tan Yin-Cai; Poulose Shibu; Olanow C Warren; Huang Xin-Yun; Yue Zhenyu
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Journal of neurochemistry 2007;103(1):238-47.
-
2007: Olanow C Warren
The pathogenesis of cell death in Parkinson's disease--2007.
Movement disorders : official journal of the Movement Disorder Society 2007;22 Suppl 17():S335-42.
-
2007: Olanow C Warren; Watkins Paul B
Tolcapone: an efficacy and safety review (2007).
Clinical neuropharmacology 2007;30(5):287-94.
-
2007: Perl Daniel P; Olanow C Warren
The neuropathology of manganese-induced Parkinsonism.
Journal of neuropathology and experimental neurology 2007;66(8):675-82.
-
2007: Martinez-Martin Pablo; Schapira Anthony H V; Stocchi Fabrizio; Sethi Kapil; Odin Per; MacPhee Graeme; Brown Richard G; Naidu Yogini; Clayton Lisa; Abe Kazuo; Tsuboi Yoshio; MacMahon Dough; Barone Paolo; Rabey Martin; Bonuccelli Ubaldo; Forbes Alison; Breen Kieran; Tluk Susanne; Olanow C Warren; Thomas Sue; Rye David; Hand Annette; Williams Adrian J; Ondo William; Chaudhuri K Ray
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.
Movement disorders : official journal of the Movement Disorder Society 2007;22(11):1623-9.
-
2007: Kieburtz Karl; Olanow C Warren
Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy.
The Mount Sinai journal of medicine, New York 2007;74(1):7-14.
-
2007: Lippa C F; Duda J E; Grossman M; Hurtig H I; Aarsland D; Boeve B F; Brooks D J; Dickson D W; Dubois B; Emre M; Fahn S; Farmer J M; Galasko D; Galvin J E; Goetz C G; Growdon J H; Gwinn-Hardy K A; Hardy J; Heutink P; Iwatsubo T; Kosaka K; Lee V M-Y; Leverenz J B; Masliah E; McKeith I G; Nussbaum R L; Olanow C W; Ravina B M; Singleton A B; Tanner C M; Trojanowski J Q; Wszolek Z K;
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
Neurology 2007;68(11):812-9.
-
2007: Goetz Christopher G; Fahn Stanley; Martinez-Martin Pablo; Poewe Werner; Sampaio Cristina; Stebbins Glenn T; Stern Matthew B; Tilley Barbara C; Dodel Richard; Dubois Bruno; Holloway Robert; Jankovic Joseph; Kulisevsky Jaime; Lang Anthony E; Lees Andrew; Leurgans Sue; LeWitt Peter A; Nyenhuis David; Olanow C Warren; Rascol Olivier; Schrag Anette; Teresi Jeanne A; Van Hilten Jacobus J; LaPelle Nancy
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Movement disorders : official journal of the Movement Disorder Society 2007;22(1):41-7.
-
2007: Goetz Christopher G; Damier Philippe; Hicking Christine; Laska Eugene; Müller Thomas; Olanow C Warren; Rascol Olivier; Russ Hermann
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Movement disorders : official journal of the Movement Disorder Society 2007;22(2):179-86.
-
2006: Olanow C Warren; Schapira Anthony H V; LeWitt Peter A; Kieburtz Karl; Sauer Dirk; Olivieri Gianfranco; Pohlmann Harald; Hubble Jean
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet neurology 2006;5(12):1013-20.
-
2006: Nair Venugopalan D; McNaught Kevin St P; González-Maeso Javier; Sealfon Stuart C; Olanow C Warren
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition.
The Journal of biological chemistry 2006;281(51):39550-60.
-
2006: Olanow C Warren; McNaught Kevin St P
Ubiquitin-proteasome system and Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(11):1806-23.
-
2006: McNaught Kevin St P; Olanow C Warren
Proteasome inhibitor-induced model of Parkinson's disease.
Annals of neurology 2006;60(2):243-7.
-
2006: Olanow C Warren; Obeso Jose A; Stocchi Fabrizio
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Lancet neurology 2006;5(8):677-87.
-
2006: Olanow C Warren; Obeso José A; Stocchi Fabrizio
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Nature clinical practice. Neurology 2006;2(7):382-92.
-
2006: Chaudhuri Kallol Ray; Martinez-Martin Pablo; Schapira Anthony H V; Stocchi Fabrizio; Sethi Kapil; Odin Per; Brown Richard G; Koller William; Barone Paolo; MacPhee Graeme; Kelly Linda; Rabey Martin; MacMahon Doug; Thomas Sue; Ondo William; Rye David; Forbes Alison; Tluk Susanne; Dhawan Vandana; Bowron Annette; Williams Adrian J; Olanow Charles W
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.
Movement disorders : official journal of the Movement Disorder Society 2006;21(7):916-23.
-
2006: Dass Biplob; Olanow C Warren; Kordower Jeffrey H
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease.
Neurology 2006;66(10 Suppl 4):S89-103.
-
2006: Olanow C Warren
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Neurology 2006;66(10 Suppl 4):S69-79.
-
2006: McNaught Kevin St P; Jackson Tehone; JnoBaptiste Ruth; Kapustin Alexander; Olanow C Warren
Proteasomal dysfunction in sporadic Parkinson's disease.
Neurology 2006;66(10 Suppl 4):S37-49.
-
2006: Jenner Peter; Olanow C Warren
The pathogenesis of cell death in Parkinson's disease.
Neurology 2006;66(10 Suppl 4):S24-36.
-
2006: McNaught Kevin St P; Olanow C Warren
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.
Neurobiology of aging 2006;27(4):530-45.
-
2006: Olanow C Warren
Movement disorders: a step in the right direction.
Lancet neurology 2006;5(1):3-5.
-
2006: Cho Catherine; Osaki Yasuhiro; Kunin Mikhail; Cohen Bernard; Olanow C Warren; Raphan Theodore
A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 2006;1():1228-31.
-
2005: Goldman S M; Tanner C M; Olanow C W; Watts R L; Field R D; Langston J W
Occupation and parkinsonism in three movement disorders clinics.
Neurology 2005;65(9):1430-5.
-
2005: Olanow C Warren
Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease.
Archives of neurology 2005;62(9):1343-4.
-
2005: Lang Anthony E; Miyasaki Janis; Olanow C Warren; Stoessl A Jon; Suchowersky Oksana
Progress in clinical neurosciences: a forum on the early management of Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2005;32(3):277-86.
-
2005: Snyder Brian J; Olanow C Warren
Stem cell treatment for Parkinson's disease: an update for 2005.
Current opinion in neurology 2005;18(4):376-85.
-
2005: Tse Winona; Liu Yiming; Barthlen Gabriele M; Hälbig Thomas D; Tolgyesi Sonia V; Gracies Jean-Michel; Olanow C Warren; Koller William C
Clinical usefulness of the Parkinson's disease sleep scale.
Parkinsonism & related disorders 2005;11(5):317-21.
-
2005: Stocchi Fabrizio; Vacca Laura; Ruggieri Stefano; Olanow C Warren
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
Archives of neurology 2005;62(6):905-10.
-
2005: Shashidharan P; Sandu D; Potla U; Armata I A; Walker R H; McNaught K S; Weisz D; Sreenath T; Brin M F; Olanow C W
Transgenic mouse model of early-onset DYT1 dystonia.
Human molecular genetics 2005;14(1):125-33.
-
2005: Olanow C Warren; Jankovic Joseph
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Movement disorders : official journal of the Movement Disorder Society 2005;20 Suppl 11():S3-10.
-
2004: Fahn Stanley; Oakes David; Shoulson Ira; Kieburtz Karl; Rudolph Alice; Lang Anthony; Olanow C Warren; Tanner Caroline; Marek Kenneth;
Levodopa and the progression of Parkinson's disease.
The New England journal of medicine 2004;351(24):2498-508.
-
2004: Hälbig Thomas D; Tse Winona; Olanow C Warren
Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
Neurologic clinics 2004;22(3 Suppl):S1-S17.
-
2004: Morrison C E; Borod J C; Brin M F; Hälbig T D; Olanow C W
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1333-41.
-
2004: Mytilineou C; McNaught K St P; Shashidharan P; Yabut J; Baptiste R J; Parnandi A; Olanow C W
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1237-51.
-
2004: Olanow C W; Kieburtz K; Stern M; Watts R; Langston J W; Guarnieri M; Hubble J;
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Archives of neurology 2004;61(10):1563-8.
-
2004: McNaught Kevin St P; Kapustin Alexander; Jackson Tehone; Jengelley Toni-Ann; Jnobaptiste Ruth; Shashidharan Pullanipally; Perl Daniel P; Pasik Pedro; Olanow C Warren
Brainstem pathology in DYT1 primary torsion dystonia.
Annals of neurology 2004;56(4):540-7.
-
2004: Olanow C Warren; Agid Yves; Mizuno Yoshi; Albanese Alberto; Bonuccelli Ubaldo; Damier Philip; De Yebenes Justo; Gershanik Oscar; Guttman Mark; Grandas F; Hallett Mark; Hornykiewicz Ole; Jenner Peter; Katzenschlager R; Langston William J; LeWitt Peter; Melamed Eldad; Mena M A; Michel P P; Mytilineou Catherine; Obeso Jose A; Poewe Werner; Quinn Niall; Raisman-Vozari R; Rajput Ali H; Rascol Olivier; Sampaio Christina; Stocchi Fabrizio
Levodopa in the treatment of Parkinson's disease: current controversies.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):997-1005.
-
2004: Stern Matthew B; Marek Kenneth L; Friedman Joseph; Hauser Robert A; LeWitt Peter A; Tarsy Daniel; Olanow C Warren
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Movement disorders : official journal of the Movement Disorder Society 2004;19(8):916-23.
-
2004: Tse Winona; Cersosimo Maria G; Gracies Jean-Michel; Morgello Susan; Olanow C Warren; Koller William
Movement disorders and AIDS: a review.
Parkinsonism & related disorders 2004;10(6):323-34.
-
2004: Olanow C Warren; Perl Daniel P; DeMartino George N; McNaught Kevin St P
Lewy-body formation is an aggresome-related process: a hypothesis.
Lancet neurology 2004;3(8):496-503.
-
2004: Germano Isabelle M; Gracies Jean-Michel; Weisz Donald J; Tse Winona; Koller William C; Olanow C Warren
Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study.
Journal of neurosurgery 2004;101(1):36-42.
-
2004: McNaught Kevin St P; Perl Daniel P; Brownell Anna-Liisa; Olanow C Warren
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
Annals of neurology 2004;56(1):149-62.
-
2004: Olanow C Warren
Melvin David Yahr, MD (1917-2004).
Neurology 2004;62(11):1932-3.
-
2004: Nair Venugopalan D; Yuen Tony; Olanow C Warren; Sealfon Stuart C
Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress.
The Journal of biological chemistry 2004;279(26):27494-501.
-
2004: Olanow C Warren; Damier Philippe; Goetz Christopher G; Mueller Thomas; Nutt John; Rascol Olivier; Serbanescu Alexandru; Deckers Frieda; Russ Hermann
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
Clinical neuropharmacology 2004;27(2):58-62.
-
2004: Olanow C W
Manganese-induced parkinsonism and Parkinson's disease.
Annals of the New York Academy of Sciences 2004;1012():209-23.
-
2004: Morrison C E; Borod J C; Perrine K; Beric A; Brin M F; Rezai A; Kelly P; Sterio D; Germano I; Weisz D; Olanow C W
Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease.
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2004;19(2):165-81.
-
2004: Shashidharan P; Paris Nicolae; Sandu Daniela; Karthikeyan Laina; McNaught Kevin St P; Walker Ruth H; Olanow C Warren
Overexpression of torsinA in PC12 cells protects against toxicity.
Journal of neurochemistry 2004;88(4):1019-25.
-
2004: Schapira Anthony H V; Olanow C Warren
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
JAMA : the journal of the American Medical Association 2004;291(3):358-64.
-
2004: Kramer Brian C; Yabut Jocelyn A; Cheong Julie; Jnobaptiste Ruth; Robakis Thalia; Olanow C Warren; Mytilineou Catherine
Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites.
The European journal of neuroscience 2004;19(2):280-6.
-
2004: Olanow C Warren; Stocchi Fabrizio
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
Neurology 2004;62(1 Suppl 1):S72-81.
-
2004: Stocchi Fabrizio; Olanow C Warren
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
Neurology 2004;62(1 Suppl 1):S56-63.
-
2004: Olanow C Warren
The scientific basis for the current treatment of Parkinson's disease.
Annual review of medicine 2004;55():41-60.
-
2003: Olanow C Warren
Present and future directions in the management of motor complications in patients with advanced PD.
Neurology 2003;61(6 Suppl 3):S24-33.
-
2003: Olanow C Warren; Goetz Christopher G; Kordower Jeffrey H; Stoessl A Jon; Sossi Vesna; Brin Mitchell F; Shannon Kathleen M; Nauert G Michael; Perl Daniel P; Godbold James; Freeman Thomas B
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.
Annals of neurology 2003;54(3):403-14.
-
2003: Roth Thomas; Rye David B; Borchert Leona D; Bartlett Cindy; Bliwise Donald L; Cantor Charles; Gorell Jay M; Hubble Jean P; Musch Bruno; Olanow C Warren; Pollak Charles; Stern Matt B; Watts Ray L
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
Sleep medicine 2003;4(4):275-80.
-
2003: Nair Venugopalan D; Olanow C Warren; Sealfon Stuart C
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.
The Biochemical journal 2003;373(Pt 1):25-32.
-
2003: Brodsky Matthew A; Godbold James; Roth Tom; Olanow C Warren
Sleepiness in Parkinson's disease: a controlled study.
Movement disorders : official journal of the Movement Disorder Society 2003;18(6):668-72.
-
2003: Bhattacharya K F; Nouri S; Olanow C W; Yahr M D; Kaufmann H
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Parkinsonism & related disorders 2003;9(4):221-4.
-
2003: Olanow C Warren
Dietary vitamin E and Parkinson's disease: something to chew on.
Lancet neurology 2003;2(2):74.
-
2003: Mytilineou Catherine; Walker Ruth H; JnoBaptiste Ruth; Olanow C Warren
Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.
The Journal of pharmacology and experimental therapeutics 2003;304(2):792-800.
-
2003: McNaught Kevin St P; Belizaire Roger; Isacson Ole; Jenner Peter; Olanow C Warren
Altered proteasomal function in sporadic Parkinson's disease.
Experimental neurology 2003;179(1):38-46.
-
2003: Schapira Anthony H V; Olanow C Warren
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.
Annals of neurology 2003;53 Suppl 3():S149-57; discussion S157-9.
-
2003: Stocchi Fabrizio; Olanow C Warren
Neuroprotection in Parkinson's disease: clinical trials.
Annals of neurology 2003;53 Suppl 3():S87-97; discussion S97-9.
-
2003: McNaught Kevin St P; Olanow C Warren
Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
Annals of neurology 2003;53 Suppl 3():S73-84; discussion S84-6.
-
2003: Olanow C Warren; Schapira Anthony H V; Agid Yves
Neuroprotection for Parkinson's disease: prospects and promises.
Annals of neurology 2003;53 Suppl 3():S1-2.
-
2002: McNaught Kevin St P; Shashidharan P; Perl Daniel P; Jenner Peter; Olanow C Warren
Aggresome-related biogenesis of Lewy bodies.
The European journal of neuroscience 2002;16(11):2136-48.
-
2002: Olanow C W
Surgical therapy for Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2002;9 Suppl 3():31-9.
-
2002: Stocchi Fabrizio; Ruggieri Stefano; Vacca Laura; Olanow C Warren
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
Brain : a journal of neurology 2002;125(Pt 9):2058-66.
-
2002: Agid Y; Olanow C W; Mizuno Y
Levodopa: why the controversy?
Lancet 2002;360(9332):575.
-
2002: McNaught Kevin St P; Björklund Lars M; Belizaire Roger; Isacson Ole; Jenner Peter; Olanow C Warren
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
Neuroreport 2002;13(11):1437-41.
-
2002: McNaught Kevin St P; Belizaire Roger; Jenner Peter; Olanow C Warren; Isacson Ole
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.
Neuroscience letters 2002;326(3):155-8.
-
2002: Shoulson Ira; Oakes David; Fahn Stanley; Lang Anthony; Langston J William; LeWitt Peter; Olanow C Warren; Penney John B; Tanner Caroline; Kieburtz Karl; Rudolph Alice;
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Annals of neurology 2002;51(5):604-12.
-
2002: McNaught Kevin St P; Mytilineou Catherine; Jnobaptiste Ruth; Yabut Jocelyn; Shashidharan P; Jennert Peter; Olanow C Warren
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
Journal of neurochemistry 2002;81(2):301-6.
-
2002: Olanow C Warren
The role of dopamine agonists in the treatment of early Parkinson's disease.
Neurology 2002;58(4 Suppl 1):S33-41.
-
2002: Kramer B C; Yabut J A; Cheong J; JnoBaptiste R; Robakis T; Olanow C W; Mytilineou C
Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection.
Neuroscience 2002;114(2):361-72.
-
2001: Cubo E; Gracies J M; Benabou R; Olanow C W; Raman R; Leurgans S; Goetz C G
Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
Archives of neurology 2001;58(9):1379-82.
-
2001: McNaught K S; Olanow C W; Halliwell B; Isacson O; Jenner P
Failure of the ubiquitin-proteasome system in Parkinson's disease.
Nature reviews. Neuroscience 2001;2(8):589-94.
-
2001: Olanow C W; Freeman T; Kordower J
Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
The New England journal of medicine 2001;345(2):146; author reply 147.
-
2001: Olanow C W; Watts R L; Koller W C
An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.
Neurology 2001;56(11 Suppl 5):S1-S88.
-
2001: Olanow C W; Brin M F
Surgical therapies for Parkinson's disease. A physician's perspective.
Advances in neurology 2001;86():421-33.
-
2000: Sealfon S C; Olanow C W
Dopamine receptors: from structure to behavior.
Trends in neurosciences 2000;23(10 Suppl):S34-40.
-
2000: Obeso J A; Rodríguez-Oroz M C; Rodríguez M; Lanciego J L; Artieda J; Gonzalo N; Olanow C W
Pathophysiology of the basal ganglia in Parkinson's disease.
Trends in neurosciences 2000;23(10 Suppl):S8-19.
-
2000: Obeso J A; Olanow C W; Nutt J G
Levodopa motor complications in Parkinson's disease.
Trends in neurosciences 2000;23(10 Suppl):S2-7.
-
2000: Shashidharan P; Good P F; Hsu A; Perl D P; Brin M F; Olanow C W
TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.
Brain research 2000;877(2):379-81.
-
2000: Morrison C E; Borod J C; Brin M F; Raskin S A; Germano I M; Weisz D J; Olanow C W
A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data.
Neuropsychiatry, neuropsychology, and behavioral neurology 2000;13(3):204-19.
-
2000: Olanow C W; Stocchi F
Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2000;7 Suppl 1():3-8.
-
2000: Hauser R A; Koller W C; Hubble J P; Malapira T; Busenbark K; Olanow C W
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Movement disorders : official journal of the Movement Disorder Society 2000;15(3):485-9.
-
2000: Olanow C W; Obeso J A
Preventing levodopa-induced dyskinesias.
Annals of neurology 2000;47(4 Suppl 1):S167-76; discussion S176-8.
-
2000: Obeso J A; Rodriguez-Oroz M C; Rodriguez M; DeLong M R; Olanow C W
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
Annals of neurology 2000;47(4 Suppl 1):S22-32; discussion S32-4.
-
2000: Tagliati M; Perl D P; Drayer B; Olanow C W
Progressive dementia and gait disorder in a 78 year old woman.
Journal of neurology, neurosurgery, and psychiatry 2000;68(4):526-31.
-
2000: Olanow C W; Schapira A H; Roth T
Waking up to sleep episodes in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2000;15(2):212-5.
-
2000: Olanow C W
Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.
Archives of neurology 2000;57(2):263-7.
-
2000: Shashidharan P; Kramer B C; Walker R H; Olanow C W; Brin M F
Immunohistochemical localization and distribution of torsinA in normal human and rat brain.
Brain research 2000;853(2):197-206.
-
2000: Olanow C W; Schapira A H; Roth T
Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole.
Neurology 2000;54(1):274; author reply 276-7.
-
2000: Olanow C W; Brin M F; Obeso J A
The role of deep brain stimulation as a surgical treatment for Parkinson's disease.
Neurology 2000;55(12 Suppl 6):S60-6.
-
2000: Olanow C W; Obeso J A
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
Neurology 2000;55(11 Suppl 4):S72-7; discussion S78-81.
-
2000: Schapira A H; Obeso J A; Olanow C W
The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
Neurology 2000;55(11 Suppl 4):S65-8; discussion S69-71.
-
2000: Obeso J A; Rodriguez-Oroz M C; Chana P; Lera G; Rodriguez M; Olanow C W
The evolution and origin of motor complications in Parkinson's disease.
Neurology 2000;55(11 Suppl 4):S13-20; discussion S21-3.
-
1999: Olanow C W
A rational approach to the treatment of early Parkinson's disease.
Parkinsonism & related disorders 1999;5(4):217-20.
-
1999: Freeman T B; Vawter D E; Leaverton P E; Godbold J H; Hauser R A; Goetz C G; Olanow C W
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease.
The New England journal of medicine 1999;341(13):988-92.
-
1999: Mytilineou C; Kokotos Leonardi E T; Kramer B C; Jamindar T; Olanow C W
Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures.
Journal of neurochemistry 1999;73(1):112-9.
-
1999: Walker R H; Spiera H; Brin M F; Olanow C W
Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature.
Movement disorders : official journal of the Movement Disorder Society 1999;14(2):262-8.
-
1999: Tatton W G; Olanow C W
Apoptosis in neurodegenerative diseases: the role of mitochondria.
Biochimica et biophysica acta 1999;1410(2):195-213.
-
1999: Hauser R A; Freeman T B; Snow B J; Nauert M; Gauger L; Kordower J H; Olanow C W
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease.
Archives of neurology 1999;56(2):179-87.
-
1999: Melamed E; Olanow C W; Nutt J G; Lang A E
Dyskinesias assessment workshop: reports from the working groups.
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():69-73.
-
1999: Olanow C W; Tatton W G
Etiology and pathogenesis of Parkinson's disease.
Annual review of neuroscience 1999;22():123-44.
-
1998: Lieberman A; Olanow C W; Sethi K; Swanson P; Waters C H; Fahn S; Hurtig H; Yahr M
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.
Neurology 1998;51(4):1057-62.
-
1998: Marsden C D; Olanow C W
The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality.
Annals of neurology 1998;44(3 Suppl 1):S189-96.
-
1998: Rodriguez M C; Obeso J A; Olanow C W
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.
Annals of neurology 1998;44(3 Suppl 1):S175-88.
-
1998: Olanow C W; Jenner P; Brooks D
Dopamine agonists and neuroprotection in Parkinson's disease.
Annals of neurology 1998;44(3 Suppl 1):S167-74.
-
1998: Tatton N A; Maclean-Fraser A; Tatton W G; Perl D P; Olanow C W
A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease.
Annals of neurology 1998;44(3 Suppl 1):S142-8.
-
1998: Jenner P; Olanow C W
Understanding cell death in Parkinson's disease.
Annals of neurology 1998;44(3 Suppl 1):S72-84.
-
1998: Perl D P; Olanow C W; Calne D
Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration?
Annals of neurology 1998;44(3 Suppl 1):S19-31.
-
1998: Olanow C W; Myllylä V V; Sotaniemi K A; Larsen J P; Pålhagen S; Przuntek H; Heinonen E H; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne U K
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Neurology 1998;51(3):825-30.
-
1998: Kordower J H; Freeman T B; Chen E Y; Mufson E J; Sanberg P R; Hauser R A; Snow B; Olanow C W
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):383-93.
-
1998: Good P F; Hsu A; Werner P; Perl D P; Olanow C W
Protein nitration in Parkinson's disease.
Journal of neuropathology and experimental neurology 1998;57(4):338-42.
-
1998: Olanow C W; Koller W C
An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.
Neurology 1998;50(3 Suppl 3):S1-57.
-
1998: Mytilineou C; Leonardi E K; Radcliffe P; Heinonen E H; Han S K; Werner P; Cohen G; Olanow C W
Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.
The Journal of pharmacology and experimental therapeutics 1998;284(2):700-6.
-
1998: Kordower J H; Freeman T B; Olanow C W
Neuropathology of fetal nigral grafts in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13 Suppl 1():88-95.
-
1998: Olanow C W; Mytilineou C; Tatton W
Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13 Suppl 1():55-8.
-
1997: Holt D A; Nauert G M; Othberg A I; Randall T S; Willing A E; Widen R H; Hauser R A; Sanberg P R; Olanow C W; Freeman T B
Infectious issues in human fetal neural transplantation.
Cell transplantation 1997;6(6):553-6.
-
1997: Sengstock G J; Zawia N H; Olanow C W; Dunn A J; Arendash G W
Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration.
Biological trace element research 1997;58(3):177-95.
-
1997: Koller W; Pahwa R; Busenbark K; Hubble J; Wilkinson S; Lang A; Tuite P; Sime E; Lazano A; Hauser R; Malapira T; Smith D; Tarsy D; Miyawaki E; Norregaard T; Kormos T; Olanow C W
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor.
Annals of neurology 1997;42(3):292-9.
-
1997: Olanow C W
Attempts to obtain neuroprotection in Parkinson's disease.
Neurology 1997;49(1 Suppl 1):S26-33.
-
1997: Freeman T B; Vawter D; Goetz C G; Leaverton P E; Hauser R A; Sanberg P R; Godbold J H; Olanow C W
Toward the use of surgical placebo-controlled trials.
Transplantation proceedings 1997;29(4):1925.
-
1997: Kordower J H; Freeman T B; Bakay R A; Goetz C G; Olanow C W
Treatment with fetal allografts.
Neurology 1997;48(6):1737-8.
-
1997: Kordower J H; Styren S; Clarke M; DeKosky S T; Olanow C W; Freeman T B
Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants.
Cell transplantation 1997;6(3):213-9.
-
1997: Kordower J H; Goetz C G; Freeman T B; Olanow C W
Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery.
Experimental neurology 1997;144(1):41-6.
-
1997: Mytilineou C; Radcliffe P M; Olanow C W
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
Journal of neurochemistry 1997;68(1):434-6.
-
1997: Mytilineou C; Radcliffe P; Leonardi E K; Werner P; Olanow C W
L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
Journal of neurochemistry 1997;68(1):33-9.
-
1997: Olanow C W; Freeman T B; Kordower J H
Neural transplantation as a therapy for Parkinson's disease.
Advances in neurology 1997;74():249-69.
-
1996: Olanow C W; Fahn S; Langston J W; Godbold J
Selegiline and mortality in Parkinson's disease.
Annals of neurology 1996;40(6):841-5.
-
1996: Olanow C W
Selegiline: current perspectives on issues related to neuroprotection and mortality.
Neurology 1996;47(6 Suppl 3):S210-6.
-
1996: Jenner P; Olanow C W
Oxidative stress and the pathogenesis of Parkinson's disease.
Neurology 1996;47(6 Suppl 3):S161-70.
-
1996: Hauser R A; Murtaugh F R; Akhter K; Gold M; Olanow C W
Magnetic resonance imaging of corticobasal degeneration.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 1996;6(4):222-6.
-
1996: Olanow C W
GPi pallidotomy--have we made a dent in Parkinson's disease?
Annals of neurology 1996;40(3):341-3.
-
1996: Good P F; Werner P; Hsu A; Olanow C W; Perl D P
Evidence of neuronal oxidative damage in Alzheimer's disease.
The American journal of pathology 1996;149(1):21-8.
-
1996: Kordower J H; Rosenstein J M; Collier T J; Burke M A; Chen E Y; Li J M; Martel L; Levey A E; Mufson E J; Freeman T B; Olanow C W
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies.
The Journal of comparative neurology 1996;370(2):203-30.
-
1996: Hauser R A; Zesiewicz T A; Martinez C; Rosemurgy A S; Olanow C W
Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1996;23(2):95-8.
-
1996: Olanow C W; Kordower J H; Freeman T B
Fetal nigral transplantation as a therapy for Parkinson's disease.
Trends in neurosciences 1996;19(3):102-9.
-
1996: Olanow C W; Godbold J H; Koller W
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
BMJ (Clinical research ed.) 1996;312(7032):702-3; author reply 704-5.
-
1996: Olanow C W
A 61-year-old man with Parkinson's disease.
JAMA : the journal of the American Medical Association 1996;275(9):716-22.
-
1996: Olanow C W; Good P F; Shinotoh H; Hewitt K A; Vingerhoets F; Snow B J; Beal M F; Calne D B; Perl D P
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study.
Neurology 1996;46(2):492-8.
-
1996: Olanow C W
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Journal of neural transmission. Supplementum 1996;48():75-84.
-
1996: Buée Scherrer V; Hof P R; Buée L; Leveugle B; Vermersch P; Perl D P; Olanow C W; Delacourte A
Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease.
Acta neuropathologica 1996;91(4):351-9.
-
1995: Olanow C W; Hauser R A; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Annals of neurology 1995;38(5):771-7.
-
1995: Freeman T B; Olanow C W; Hauser R A; Nauert G M; Smith D A; Borlongan C V; Sanberg P R; Holt D A; Kordower J H; Vingerhoets F J
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.
Annals of neurology 1995;38(3):379-88.
-
1995: Lang A E; Benabid A L; Koller W C; Lozano A M; Obeso J A; Olanow C W; Pollak P
The core assessment program for intracerebral transplantation.
Movement disorders : official journal of the Movement Disorder Society 1995;10(4):527-8.
-
1995: McDermott M P; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz C G; Golbe L I; Koller W; Lang A E; Olanow C W
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
Archives of neurology 1995;52(6):565-70.
-
1995: Freeman T B; Sanberg P R; Nauert G M; Boss B D; Spector D; Olanow C W; Kordower J H
The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts.
Cell transplantation 1995;4(1):141-54.
-
1994: Hauser R A; Zesiewicz T A; Rosemurgy A S; Martinez C; Olanow C W
Manganese intoxication and chronic liver failure.
Annals of neurology 1994;36(6):871-5.
-
1994: Olanow C W; Arendash G W
Metals and free radicals in neurodegeneration.
Current opinion in neurology 1994;7(6):548-58.
-
1994: Sengstock G J; Olanow C W; Dunn A J; Barone S; Arendash G W
Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
Experimental neurology 1994;130(1):82-94.
-
1994: Oestreicher E; Sengstock G J; Riederer P; Olanow C W; Dunn A J; Arendash G W
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study.
Brain research 1994;660(1):8-18.
-
1994: Hauser R A; Olanow C W
Magnetic resonance imaging of neurodegenerative diseases.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 1994;4(3):146-58.
-
1994: Olanow C W; Marsden C D; Lang A E; Goetz C G
The role of surgery in Parkinson's disease management.
Neurology 1994;44(3 Suppl 1):S17-20.
-
1994: Olanow C W; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes J D; Jankovic J
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1994;9(1):40-7.
-
1993: Olanow C W
A radical hypothesis for neurodegeneration.
Trends in neurosciences 1993;16(11):439-44.
-
1993: Hauser R A; Olanow C W
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(4):512-4.
-
1993: Woodward W R; Olanow C W; Beckner R M; Hauser R A; Gauger L L; Cedarbaum J M; Nutt J G
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Neurology 1993;43(9):1704-8.
-
1993: Sengstock G J; Olanow C W; Menzies R A; Dunn A J; Arendash G W
Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.
Journal of neuroscience research 1993;35(1):67-82.
-
1993: Olanow C W
A scientific rationale for protective therapy in Parkinson's disease.
Journal of neural transmission. General section 1993;91(2-3):161-80.
-
1993: Olanow C W
MAO-B inhibitors in Parkinson's disease.
Advances in neurology 1993;60():666-71.
-
1993: Olanow C W
A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8 Suppl 1():S1-7.
-
1992: Good P F; Olanow C W; Perl D P
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.
Brain research 1992;593(2):343-6.
-
1992: Olanow C W
Magnetic resonance imaging in parkinsonism.
Neurologic clinics 1992;10(2):405-20.
-
1992: Sengstock G J; Olanow C W; Dunn A J; Arendash G W
Iron induces degeneration of nigrostriatal neurons.
Brain research bulletin 1992;28(4):645-9.
-
1992: Olanow C W; Calne D
Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
Neurology 1992;42(4 Suppl 4):13-26; discussion 41-8.
-
1992: Olanow C W
A rationale for dopamine agonists as primary therapy for Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1992;19(1 Suppl):108-12.
-
1992: Olanow C W
An introduction to the free radical hypothesis in Parkinson's disease.
Annals of neurology 1992;32 Suppl():S2-9.
-
1992: Olanow C W
Early therapy for Parkinson's disease.
European neurology 1992;32 Suppl 1():30-5.
-
1991: Hauser R A; Olanow C W
Early therapy for Parkinson's disease.
Archives of neurology 1991;48(10):1009-10.
-
1991: Cedarbaum J M; Olanow C W
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Neurology 1991;41(10):1567-70.
-
1991: Freeman T B; Spence M S; Boss B D; Spector D H; Strecker R E; Olanow C W; Kordower J H
Development of dopaminergic neurons in the human substantia nigra.
Experimental neurology 1991;113(3):344-53.
-
1991: Olanow C W; Nakano K; Nausieda P; Tetrud J A; Manyam B; Last B; Block G; Liss C; Bush D
An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Clinical neuropharmacology 1991;14(3):235-40.
-
1991: Olanow C W; Gauger L L; Cedarbaum J M
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Annals of neurology 1991;29(5):556-9.
-
1990: Olanow C W; Koller W; Goetz C G; Stebbins G T; Cahill D W; Gauger L L; Morantz R; Penn R D; Tanner C M; Klawans H L
Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results.
Archives of neurology 1990;47(12):1286-9.
-
1990: Olanow C W
Oxidation reactions in Parkinson's disease.
Neurology 1990;40(10 Suppl 3):suppl 32-7; discussion 37-9.
-
1990: Jankovic J; McDermott M; Carter J; Gauthier S; Goetz C; Golbe L; Huber S; Koller W; Olanow C; Shoulson I
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group.
Neurology 1990;40(10):1529-34.
-
1990: Cahill D W; Olanow C W
Autologous adrenal medulla to caudate nucleus transplantation in advanced Parkinson's disease: 18 month results.
Progress in brain research 1990;82():637-42.
-
1989: Olanow C W; Werner E G; Gauger L L
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Clinical neuropharmacology 1989;12(6):490-7.
-
1989: Werner E G; Olanow C W
Parkinsonism and amiodarone therapy.
Annals of neurology 1989;25(6):630-2.
-
1989: Goetz C G; Olanow C W; Koller W C; Penn R D; Cahill D; Morantz R; Stebbins G; Tanner C M; Klawans H L; Shannon K M
Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease.
The New England journal of medicine 1989;320(6):337-41.
-
1987: Olanow C W; Alberts M J
Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease.
Clinical neuropharmacology 1987;10(2):178-85.
-
1987: Olanow C W; Alberts M J
Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Advances in neurology 1987;45():555-60.
-
1987: Olanow C W; Wechsler A S; Sirotkin-Roses M; Stajich J; Roses A D
Thymectomy as primary therapy in myasthenia gravis.
Annals of the New York Academy of Sciences 1987;505():595-606.
-
1985: Ross D R; Coffey C E; Massey E W; Olanow C W
Depression and benign intracranial hypertension.
Psychosomatics 1985;26(5):387-9, 393.
-
1984: Olanow C W; Roses A D
AChR antibody titer and clinical response to thymectomy in MG.
Neurology 1984;34(7):987-8.
-
1984: Sabina R L; Swain J L; Olanow C W; Bradley W G; Fishbein W N; DiMauro S; Holmes E W
Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.
The Journal of clinical investigation 1984;73(3):720-30.
-
1984: Greenberg S J; Olanow C W; Dawson D V; Crane B; Roses A D
Autologous mixed lymphocyte reaction in patients with myasthenia gravis: correlation with disease activity.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(3):1229-36.
-
1984: Olanow C W; Roses A
A new approach to late onset myasthenia gravis.
Geriatrics 1984;39(1):91-3, 97-9.
-
1984: Coffey C E; Ross D R; Massey E W; Olanow C W
Dyskinesias associated with lithium therapy in parkinsonism.
Clinical neuropharmacology 1984;7(3):223-9.
-
1983: Haynes B F; Harden E A; Olanow C W; Eisenbarth G S; Wechsler A S; Hensley L L; Roses A D
Effect of thymectomy on peripheral lymphocyte subsets in myasthenia gravis: selective effect on T-cells in patients with thymic atrophy.
Journal of immunology (Baltimore, Md. : 1950) 1983;131(2):773-7.
-
1983: Austin E H; Olanow C W; Wechsler A S
Thymoma following transcervical thymectomy for myasthenia gravis.
The Annals of thoracic surgery 1983;35(5):548-50.
-
1983: Coffey C E; Ross D R; Ferren E L; Bragdon A C; Hurwitz B J; Olanow C W
The effect of lithium on the "on-off" phenomenon in parkinsonism.
Advances in neurology 1983;37():61-73.
-
1982: Coffey C E; Ross D R; Ferren E L; Sullivan J L; Olanow C W
Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate.
Annals of neurology 1982;12(4):375-9.
-
1982: Rizzo G N; Olanow C W
[Neurologic manifestations of hyperparathyroidism. Study of 120 cases]
Arquivos de neuro-psiquiatria 1982;40(3):213-22.
-
1982: Olanow C W; Wechsler A S; Roses A D
A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.
Annals of surgery 1982;196(2):113-21.
-
1982: Somerville E R; Olanow C W
Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica.
Archives of neurology 1982;39(8):527-8.
-
1982: Friedman A H; Wilkins R H; Kenan P D; Olanow C W; Dubois P J
Pituitary adenoma presenting as facial pain: report of two cases and review of the literature.
Neurosurgery 1982;10(6 Pt 1):742-5.
-
1982: Olanow C W; Lane R J; Hull K L; Roses A D
Neonatal myasthenia gravis in the infant of an asymptomatic thymectomized mother.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1982;9(2):85-7.
-
1982: Coffey C E; Ross D R; Massey E W; Olanow C W
Familial benign intracranial hypertension and depression.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1982;9(1):45-7.
-
1982: Olanow C W; Lane R J; Roses A D
Thymectomy in late-onset myasthenia gravis.
Archives of neurology 1982;39(2):82-3.
-
1981: Ross D R; Coffey C E; Ferren E L; Walker J I; Olanow C W
"On-off" syndrome treated with lithium carbonate: a case report.
The American journal of psychiatry 1981;138(12):1626-7.
-
1981: Rothman S J; Olanow C W
Brain stem glioma in childhood: acute hemiplegic onset.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1981;8(3):263-4.
-
1981: Olanow C W; Roses A D
The pathogenesis of myasthenia gravis--a hypothesis.
Medical hypotheses 1981;7(7):957-68.
-
1981: Olanow C W; Roses A D; Fay J W
The effect of plasmapheresis on post-thymectomy ocular dysfunction.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1981;8(2):169-72.
-
1981: Rizzo G N; Olanow C W; Roses A D
[Chorea in hyperparathyroidism. Report of a case]
AMB; revista da Associação Médica Brasileira 1981;27(5):155-6.
-
1981: Olanow C W; Finn A L; Prussak C
The effects of salicylate on the pharmacokinetics of phenytoin.
Neurology 1981;31(3):341-2.
-
1981: Roses A D; Olanow C W; McAdams M W; Lane R J
No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis.
Neurology 1981;31(2):220-4.
-
1981: Olanow C W; Finn A L
Phenytoin: pharmacokinetics and clinical therapeutics.
Neurosurgery 1981;8(1):112-7.
-
1981: Roses A D; Hudgson P; McAdams M W; Edwards A M; Olanow C W
On the mechanism of pathogenesis of human myasthenia gravis.
Transactions of the American Neurological Association 1981;106():212-5.
-
1981: Olanow C W
Current concepts in the management of movement disorders.
Clinical neurosurgery 1981;28():137-70.
-
1980: Wechsler A S; Olanow C W
Myasthenia gravis.
The Surgical clinics of North America 1980;60(4):931-45.
-
1979: Olanow C W; Finn A; Prussak C
The effect of salicylate on phenytoin pharmacokinetics.
Transactions of the American Neurological Association 1979;104():109-10.
-
1973: Schwartz A M; Olanow C W; Spencer A
A double-blind controlled study of MK-486 in Parkinson's disease.
Transactions of the American Neurological Association 1973;98():301-3.
Sign-in to see more
